Rebecca McKetin, Olivia M Dean, Alyna Turner, Peter J Kelly, Brendan Quinn, Dan I Lubman, Paul Dietze, Gregory Carter, Peter Higgs, Barbara Sinclair, David Reid, Amanda L Baker, Victoria Manning, Nina Te Pas, Tamsin Thomas, Ramez Bathish, Dayle K Raftery, Anna Wrobel, Lucy Saunders, Shalini Arunogiri, Frank Cordaro, Harry Hill, Scott Hall, Philip J Clare, Mohammadreza Mohebbi, Michael Berk
BACKGROUND: Methamphetamine dependence is a significant global health concern for which there are no approved medications. The cysteine prodrug, N-acetylcysteine (NAC), has been found to ameliorate glutamate dysregulation in addiction, and to reduce craving for methamphetamine and other drugs. We evaluated the efficacy and safety of NAC as a pharmacotherapy for methamphetamine dependence. METHODS: A parallel double-blind randomised placebo-controlled trial of people dependent on methamphetamine recruited from Geelong, Melbourne and Wollongong, Australia, between July 2018 and December 2019...
August 2021: EClinicalMedicine